Commodore Capital Boosts Stake in Relay Therapeutics

Hedge fund increases ownership in biotech company by over a quarter

Mar. 15, 2026 at 9:43am

Got story updates? Submit your updates here. ›

Commodore Capital LP, a hedge fund, has increased its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) by 27.3% in the third quarter. The firm now owns 17 million shares, or approximately 9.81% of the biotech company's outstanding stock, making it Relay Therapeutics' largest institutional investor.

Why it matters

This significant increase in Commodore Capital's position in Relay Therapeutics suggests the hedge fund sees strong potential in the company's drug development pipeline and future growth prospects. As a major shareholder, Commodore Capital's actions could influence the strategic direction of Relay Therapeutics.

The details

According to a 13F filing with the SEC, Commodore Capital acquired an additional 3.65 million shares of Relay Therapeutics during the third quarter, bringing its total position to 17 million shares. This makes Commodore Capital the largest institutional investor in the company, owning nearly 10% of Relay Therapeutics' outstanding stock.

  • Commodore Capital increased its stake in Relay Therapeutics during the 3rd quarter of 2026.

The players

Commodore Capital LP

A hedge fund that has significantly increased its ownership stake in Relay Therapeutics, making it the company's largest institutional investor.

Relay Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing precision therapies for oncology, headquartered in Cambridge, Massachusetts.

Got photos? Submit your photos here. ›

The takeaway

Commodore Capital's increased investment in Relay Therapeutics suggests the hedge fund sees significant potential in the biotech company's drug pipeline and future growth prospects. As a major shareholder, Commodore Capital's actions could influence Relay Therapeutics' strategic direction going forward.